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The yeast expression system for recombinant
glycosyltransferases
Martine Malissard, Steffen Zeng, Eric G. Berger*
Institute of Physiology, University Zurich, Winterthurerstr. 190, CH-8057 Zürich, Switzerland
Glycosyltransferases are increasingly being used for in vitro synthesis of oligosaccharides. Since these enzymes are
difficult to purify from natural sources, expression systems for soluble forms of the recombinant enzymes have been
developed. This review focuses on the current state of development of yeast expression systems. Two yeast species have
mainly been used, i.e. Saccharomyces cerevisiae and Pichia pastoris. Safety and ease of fermentation are well recognized
for S. cerevisiae as a biotechnological expression system; however, even soluble forms of recombinant glycosyltrans-
ferases are not secreted. In some cases, hyperglycosylation may occur. P. pastoris, by contrast, secrete soluble orthogly-
cosylated forms to the supernatant where they can be recovered in a highly purified form.
The review also covers some basic features of yeast fermentation and describes in some detail those glycosyltrans-
ferases that have successfully been expressed in yeasts. These include b1,4galactosyltransferase, a2,6sialyltransferase,
a2,3sialyltransferase, a1,3fucosyltransferase III and VI and a1,2mannosyltransferase. Current efforts in introducing glyco-
sylation systems of higher eukaryotes into yeasts are briefly addressed.
Keywords: Saccharomyces cerevisiae, Pichia pastoris, b1,4galactosyltransferase, a2,6sialyltransferase, a2,3sialyltrans-
ferase, a1,3fucosyltransferase, a1,2mannosyltransferase, glycosylation engineering
Introduction
Heteroglycans are macromolecules which exert multiple
biospecific functions by virtue of their highly ordered struc-
tures [1,2]. In recent years functions associated with their
expression on the cell surface have attracted much atten-
tion because of their important involvement in cell adhe-
sion and recognition. The paradigms for such interactions
are the selectin-mediated processes [3], host-pathogen rec-
ognition for cell-cell adhesion [4], lectin-mediated endocy-
tosis [5] and carbohydrate-mediated immune recognition
[6] for glycoprotein binding.
In some instances these interactions have been proposed
to be useful therapeutic targets: Inhibition of binding could
prevent invasion by pathogens [7], alleviate the acute
xenograft rejection [8], or the inflammatory response [9].
First generation inhibitors in general are molecules com-
prising the binding domain of the ligand. In the case of
oligosaccharide/protein interaction the choice may be
either the peptide moiety involved in binding of the oli-
gosaccharide [10] or the oligosaccharide itself. The difficul-
ties in obtaining sufficient quantities (i.e., gram scale) of the
desired glyco-compound are notorious. Although enor-
mous progress has been made in the chemical synthesis of
heterooligosaccharides [11], their synthesis at industrial
scale still appears beyond any reasonable cost-benefit ratio.
As an alternative to chemical synthesis chemo-enzymic or
even enzymic synthesis is now within the grasp of possibili-
ties.
The molecular basis for these highly specific interactions
is the structural complexity of the oligosaccharide ligand.
In vivo these are assembled by a specific class of enzymes,
the glycosyltransferases. While these enzymes have been
studied biochemically in some detail a quarter of a century
ago (for reviews, see [12]), molecular cloning and heterolo-
gous expression has significantly advanced our knowledge
(for reviews, see [13,14]).
This advance concerns mainly two topics: First, most of
these enzymes belong to gene families of enzymes whose
activities  are usually related by  their specificity  for the
donor substrate and a certain degree of structural homol-
ogy (Table 1). Second, heterologous expression not only
permits determination of their fine structural specificity
towards the acceptor substrate (which may be of critical
importance for subtle biosynthetic differences in vivo) but
allows an override of their restricted specificity by using a
large excess  of  recombinant enzyme. Thus recombinant
glycosyltransferases can be used for the synthesis of non-
natural glycosides [29,30].
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The main enzymological properties shared by all mam-
malian glycosyltransferases are listed in Table 2. While a
few glycosyltransferases isolated from natural sources (e.g.,
ST6Gal, Gal-T1) have been commercially available for
many years, other glycosyltransferases have only recently
been put on the market as recombinant enzymes. The pos-
sibility to express these enzymes in some special cases in
prokaryotes and in yeasts may facilitate their future use,
since fermentation technology costs are low. This review
focuses on the published aspects of expression and produc-
tion in yeasts and shows that this is a feasible approach to
render these enzymes generally available; in some cases
however unexpected difficulties may arise.
Basic principles of yeast fermentation
Due  to the long and extensive use of yeasts in human
nutrition, yeast cultivation has become a field of extensive
46
Table 1. Gene families of mammalian glycosyltransferases
Donor Trivial name Abbreviation Linkage Acceptor References
substrate type formed substrates
CMPNeuAc Sialyl- STX2 Acc3 n4 a2fi 3 bGal [15,16]
transferase a2fi 6 aNeuAc
a2fi 8 bGlcNAc
aGalNAc
UDPGal Galactosyl- b1,4Gal-T n4 b1fi 4 bGlcNAc [17,18]
transferase Type 2 linkage1 bGlc
UDPGal Galactosyl- b1,3Gal-T b1fi 3 bGlcNAc [19,20]
transferase Type 1 linkage1 aGalNAc
GDPFuc Fucosyl- a1,2Fuc-T a1fi 2 bGal [21]
transferases
GDPFuc Fucosyl- a1,3Fuc-T n4 a1fi 3 bGlcNAc [22]
transferases
UDPGlcNAc N-acetyl- GlcNAc-T n4 b1fi 2,3,4,6 aMan [23]
glucosaminyl-
transferases
UDPGalNAc N-acetyl- GalNAc-T a1fi peptide peptide [24,25]
galactosaminyl-
transferase
UDPGalNAc N-acetyl- GalNAc-T bfi 4 bGlcNAc [26]
galactosaminyl-
transferase
GDPMan Mannosyl- Man-T a1fi 2 a/b-mannose [27]
transferase
GDPMan Mannosyl- Man-T b1fi 2 bGlcNAc [28]
transferase
GDPXyl Xylosyl- Xyl-T
transferase
1 type 1 linkage: Galb1 Þ 3GlcNAc; type 2 linkage : Galb1 Þ 4GlcNAc
2 X refers to a linkage type (3 or 6 or 8)
3 acc, acceptor
4 n refers to a number defined by a gene product
Table 2. General properties of mammalian glycosyltrans-
ferases
Monomeric, in vivo dimeric?
Type II transmembrane protein1
Domain structure consists of cytoplasmic, transmembrane,
stem and catalytic domains (see Fig. 1)
Usually N- and/or O-glycosylated, predominantly in the stem
region
Ordered bisubstrate mechanism: binds first donor, then
acceptor substrate2
Mn21 usually cofactor
Km donor substrate: micromolar range
Km acceptor substrate: millimolar range
Catalytic activity: usually in the range of 5–20 U/mg
1 Exceptions have been described
2 Rigorous kinetic mechanisms have been determined in few cases only
126 Malissard, Zeng, and Berger
study and experience reflected in a vast number of publica-
tions. Most importantly, in the context of biosafety those
yeasts which are used for the production of human nutri-
ents are considered safe.
The following chapter briefly addresses the main prob-
lems. For more detailed information the reader is referred
to standard textbooks of biotechnology [31].
Cost-effective production of a heterologous protein in
yeasts depends on several factors. First one needs a stable,
especially in terms of genetic stability, and reproducible
process, fulfilling the legal safety restrictions for genetically
modified organisms (GMO). Second, to facilitate down
stream processing, a high final concentration of the protein
of interest is generally desirable, as well as a high produc-
tivity relative to cell number and volume. Because secreted
product concentration normally increases with the cell den-
sity, high density cultivation systems (80–200 g/l dry mass
for Saccharomyces cerevisiae on semi-synthetic media) are
of general interest.
Following a feasibility study of production in shaker
flasks, biotechnologists generally address the question of
bioreactor operation mode. Three possibilities, batch, con-
tinuous cultivation and fed-batch are available. In a batch
cultivation all substrates are given at the start of the fer-
mentation. Therefore, high initial sugar concentrations are
often applied. But these are limited by the osmotic sensitiv-
ity of the yeasts and by catabolite repression. The possibili-
ties to regulate batch processes  are very limited. Once
started they can only be influenced by changing one of the
continuous parameters like oxygen supply, pH or tempera-
ture.
A continuous cultivation allows, in theory, the control of
the whole process by manipulation of every component
over an unlimited period of time. In practice, the process is
often limited by decreasing productivity caused by the se-
lection for non-expressing clones in the system, due to ge-
netic instability. In addition, the product concentration in
the harvest is dependent on residence time and normally
lower when compared to batch processes. Further difficul-
ties can be caused by attempts to maintain a high oxygen
transfer rate (OTR) and sufficient cooling at high dilution
rates, which influences the attainable cell density and thus
the product concentration.
Fed-batch cultivation allows control of the substrate con-
centration over a limited period of time by adding nutri-
ents, trace salts and vitamins until the end of the process or
upon reaching the maximum volume of the vessel. This
high product harvest concentration and the flexibility of
the system make it still the method of choice for the expres-
sion of heterologous proteins although continuous cultiva-
tion approaches are becoming increasingly interesting.
The next step is the choice of an appropriate reactor.
Due to the lower doubling time of yeasts (1.5 h) versus
approximately 24 h for animal cell lines, monoseptic cul-
tures are generally easier to maintain than for animal cells.
The methylotrophic yeasts such as Pichia pastoris are addi-
tionally protected by the inducer methanol which is toxic
or at least growth-inhibiting for a number of other organ-
isms. Therefore, no special sterility technique is necessary.
Nevertheless, a number of other requirements have to be
fulfilled. During aerobic growth, heat production and oxy-
gen consumption are closely correlated. For each mole of
oxygen consumed 455 kJ heat is generated when grown on
glucose [32]. The specific oxygen demand of S. cerevisiae is
8 mM per h and g of cells, thus somewhat lower than that
of E. coli (which consumes 10.8). Special care has to be
taken for the DO (dissolved oxygen) due to the fact that
yeasts have the ability to switch their metabolism to etha-
nol production at low DO or high glucose concentration
[33], thereby changing byproduct formation and growth
rate. The maximum attainable cell density can thus be lim-
ited by the OTR or  the transferable heat, respectively.
Therefore, these parameters are of critical importance in
the process design, and it seems feasible to keep one of
them constant during scale-up. In order to reach high OTR,
the presence of a cell wall protecting the plasma membrane
in yeasts is of general advantage. It makes the organism
comparatively insensitive to shear stress and bubbled aera-
tion, whereas the formation of foam can limit the achiev-
able OTR. If, however, oxygen supply becomes limiting in
the process or during scale-up, aeration can be switched to
pure oxygen (maximum soluble O2 increases from 9 to 43
mg/l). In the past years an impressive number of specialized
equipment for fermentation has been put on the market.
However, the classical stirred vessel most probably due to
its flexibility, its availability from lab size to over 100 m3
scale and its comparatively well known scale-up properties
The culture conditions as well as the process design itself
is influenced by several parameters including the localiza-
tion of the protein of interest (intra- vs. extracellularly), the
regulation of the promoter (constitutive vs. induced) as
well as product stability.
For an intracellular product which is expressed under the
control of a constitutive promoter, the process design will
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Figure 1. This scheme depicts the domain structure of glycosyltrans-
ferases as first described by Paulson and Colley [134]. The scissors
mark the approximate position where membrane-bound glycosyltrans-
ferase can be converted to secretory forms [135]. TMD designates the
transmembrane domain.
The yeast expression system 127
be simply focused on the production of biomass. By con-
trast, the increasing use of inducible promoters requires at
least a two step cultivation: While in the first phase biomass
production with high growth rates is generally desirable,
the second phase will be adapted for the production of the
protein of interest at low growth rates. Expression of se-
creted products is much preferred due to three main advan-
tages: First, no disruption of the cells is needed; second, the
toxicity of the product to the host is of lesser importance;
third, down stream processing can be facilitated due to the
reduced amount of contaminant proteins. The choice of the
carbon source and of the whole media depends on the
product market price. For the production of heterologous
proteins glucose is commonly used as a carbon source. The
temperature is generally set to 28–30 8C and tightly regu-
lated.
Once the process has been successfully established in a
small scale bioreactor (typically 1–10 liter), and if higher
amounts of product are needed, scale-up will be started due
to the fact that production costs are generally inversely
related to the scale of fermentation. Depending on the
limitations of the process different scale-up criteria  are
kept constant (e.g., OTR, kLa). In a first step, a one order of
magnitude bigger bioreactor is usually investigated.
Since expression of glycosyltransferases in Pichia pas-
toris seems to be of advantage, the following section deals
with some special features in using this organism.
The methylotropic yeast P. pastoris can be grown to high
density (.100 g/l on glycerol), and has the ability to use
methanol as the sole carbon source. It is sold as a kit allow-
ing the gene of interest to be expressed under the control
of the strong inducible alcohol oxidase (AOX) promoter.
The first step of the biosynthesis is the oxidation of metha-
nol to formaldehyde and hydrogen peroxide, which is sub-
sequently detoxified by catalase while none of the energy
of   this highly   exothermous reaction is   harnessed as
NAD(P)H or ATP [34]. Additionally three moles of oxygen
are required to completely oxidize one mole of methanol,
generating 4–6 moles of ATP. Therefore heat production
and sufficient oxygen supply are, especially for Mut1 stains
(which can grow fast on methanol), parameters to be
watched during process design and scale-up. Compared to
shaker flasks cultivation in a bioreactor is expected to give
a 5 to 10 times higher yield, especially for Mut1 strains, due
to the better oxygen supply [35]. The cultivation process is
divided into two phases: In the first phase, biomass is pro-
duced using glycerol as a carbon source. Precultures are set
up in baffled flasks (5–10% initial reactor volume) and
grown to an OD600 of 2–6. Subsequently the culture is used
to inoculate the reactor containing 4% glycerol, some basic
salts and trace elements. DO is set to .20%. If the meas-
ured value reaches this critical mark and cannot be main-
tained by increasing the pressure or by switching to pure
oxygen the glycerol feed has to be reduced. The pH is
normally set at 5–6 while regulation by the addition of
ammonium hydroxide is recommended. If proteolysis turns
out to be critical, the pH can be lowered to 3 during induc-
tion. It has also been reported that a higher pH as well as a
lower temperature [36] may have the same effect on prote-
olysis. Another possibility to reduce proteolysis is to in-
clude amino acids in the media. Additionally, two strains,
SMD 1168 and 1163, deficient in Proteinase A or B have
been used to express protease sensitive peptides [37,38].
The addition of antifoam should be evaluated carefully. For
Fuc-T III  an  inhibiting  effect of  antifoam  reducing  the
activity by 70% has been reported [39]. Interestingly, tem-
peratures above 328C have been reported to reduce protein
secretion. After 18 to 24 h, glycerol will  be completely
consumed and a density of 90–150 g/l wet cells is expected.
In order to reach a higher cell density which is closely
linked to a higher product concentration, a glycerol fed-
batch step may be applied. When adding glycerol or the
inducer methanol, it is recommended to include some trace
salt. Siegel and Brierley showed that for an up-scaled proc-
ess an adapted formulation of trace salts may be favorable
[40]. After a density of 50–300 g/l of wet cells is reached
methanol is added. The two different methanol utilizing
phenotypes, Muts and Mut1 require different handling:
Muts strains grow only slowly on methanol thereby con-
suming lower amounts of methanol and require a reduced
methanol feed (1 instead 3.6 ml for Mut1 per h and l of
initial cultivation volume). Excess methanol (.1–2%) will
be toxic for the cells. Accordingly, Muts cells have a lower
oxygen consumption rate. When the culture is adapted to
methanol (normally after 2–4 h) the feed can be doubled.
After an additional 2 h the feed can again be increased to
11 for Mut1 per h and l and 3 ml/h per l of initial reactor
volume for Muts strains.
A continuous cultivation process for Pichia Mut1 has
been described: Due to the lower cell density of 100 instead
of 120 g dry cells/liter and the lower product concentration
of 350 instead of 550 mg/l of product, this approach appears
not very promising [41]. Even though a report on tetanus
toxin fragment c exists showing an expression level in the
12 g/l scale [42], Fuc-T III, the first documented glycosyl-
transferase expressed in P. pastoris, reached only a concen-
tration of 30 mg/l [39].
Vectors for expression in yeasts
The catalog of plasmid DNA vectors with different mark-
ers capable of transforming auxotrophic yeast strains for a
variety of cloning purposes has expanded greatly. With few
exceptions these plasmids also function as shuttle vectors
meaning that they possess bacterial sequences that can be
selected for and propagated in E. coli.
Two  types  of vectors  are  generally used to  construct
plasmids for yeast transformation: YEp (yeast episomal
plasmid)  and YCp (yeast centromeric plasmid)  vectors.
Both classes carry a sequence that promotes autonomous
48
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replication in yeast (ARS elements). The ARS elements
are yeast origins of DNA replication and their presence
promotes high-frequency of transformation. YCp plasmids
carry a chromosomal centromere whose sequences are im-
portant for plasmid association with the cell’s mitotic spin-
dle apparatus. As a consequence the plasmid copy number
is limited to 1–2 copies per cell.
The YEp vectors utilize the partitioning system of the
endogenous yeast plasmid or episome known as the 2l
circle to achieve stable high copy propagation [43,44]. The
relevant 2l sequences function to facilitate equal distribu-
tion of plasmid molecules between mother and daughter
cells at mitosis. Plasmids harboring 2l sequence are main-
tained at 10–40 copies per cell.
The integrating yeast (YIp) vectors are another type of
vector used for expression in yeast. Integration of DNA
sequences into the yeast chromosome has the advantage
that the yeast can grow in rich rather than selective media
to much higher culture density without risking the loss of
the desired gene. Therefore, high expression is dependent
on the choice of promoters rather than the plasmid copy
number. Two different methods have been developed to
integrate foreign DNA into the yeast chromosomes: YIp
vectors lack an origin for autonomous replication but carry
sequences which allow for high-frequency chromosomal
integration. These plasmids are linearized by a single re-
striction cut within the complementary yeast gene on the
vector for integrative gene conversion. The insertional in-
tegration event results in two copies of the “chromosomal”
gene flanking the newly inserted foreign gene. A number of
integrating vectors have been used successfully [45,46].
The second approach for gene integration, gene replace-
ment by homologous recombination (integrative gene dis-
ruption), is a relatively efficient method for directing DNA
to a particular locus in the chromosome. The DNA to be
integrated is linearized with two restriction cuts and retains
flanking sequences matching the desired chromosomal lo-
cus. The desired gene is engineered into the coding region
of the complementary gene for  chromosomal insertion,
thus disrupting its gene expression thereby substituting ex-
pression of the desired gene. This approach has also been
used for the elimination of yeast genes that could interfere
with efficient expression of the foreign protein [47].
To achieve efficient expression, vectors must contain
yeast promoter and terminator sequences for efficient tran-
scription of the foreign gene as well as selection markers.
The vector may also contain a signal sequence to direct the
expression product into the secretory pathway.
Yeast auxotrophic selection markers
The most commonly-used markers for the selection of
yeast transformants are LEU2, TRPI, URA3, HIS3 and
HIS4; they are used in corresponding mutant strains which
are auxotrophic for leucine, tryptophane, uracil and histid-
ine, respectively. Continuous selection requires the use of
minimal growth medium lacking the relevant nutrient.
Yeast promoters
For an efficient transcription of a foreign gene the use of
yeast promoters was found to be essential [48].
The first promoters used were from genes encoding
abundant glycolytic enzymes, eg. alcohol dehydrogenase I
(ADH1) [48], phosphoglycerate kinase (PGK) [49], triose
phosphate isomerase (TPI) [50,51], or glyceraldehyde-3-
phosphate dehydrogenase (GAP or GAPDH) [52] (Table
3). Glycolytic promoters are the most powerful of S. cere-
visiae, but they are poorly regulated; this makes them un-
suitable for expressing toxic proteins and inappropriate for
use in large scale culture where there is a higher risk for the
selection of non-expressing cells.
It is preferable to use a tightly-regulated promoter to
allow separation of the growth stage from the expression
stage. The most powerful tightly-regulated promoters of S.
cerevisiae are those of the galactose-regulated genes,
GAL,1 GAL7 and GAL10 involved in metabolizing galac-
tose. GAL1, GAL7 and GAL10 mRNAs are rapidly in-
duced .1000-fold to approx 1% total mRNA on addition
of galactose [59] (Table 3).
The promoter of the acid phosphatase gene PHO5 which
is regulated by inorganic phosphate concentration has been
extensively used for foreign gene expression [54]. The
structural features for regulation of the PHO5 promoter
have been studied in details (for review, see [60]).
Another type of promoter belongs to the glucose-re-
pressible promoters. Glucose-repression is a global system
regulating the expression of a number of genes including
sugar fermentation genes by the availability of glucose.
Genes involved  in sucrose  or galactose  metabolism are
transcriptionally repressed by glucose. Typical examples of
promoters regulated primarily by glucose-repression are
those encoding alcohol dehydrogenase II (ADH2) [53] or
iso-1-cytochrome c (CYC1) [55]. The ADH2 promoter is
both powerful and tightly regulated. It is repressed over
100-fold by glucose, thus it can be used for efficient expres-
sion of toxic proteins eg. insulin-like growth factor I (IGF-
I) [61]. Glucose-repressible systems have a potential
serious disadvantage in industrial fermentations: It is diffi-
cult to maintain tight glucose-repression under conditions
of glucose-limitation which is required to achieve high cell
density.
In order to reduce the drawbacks due to certain promot-
ers several hybrid promoters have been designed. The hy-
brid promoters such as ADH2/GAPDH [62] and
GAL10/CYC1 [63], resp., have also been successfully used
to express a variety of heterologous gene products. In addi-
tion to the previously described promoters other regulated
promoter systems have been described, among them the
CUP1 promoter [56]. It is tightly-regulated and inde-
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pendent of culture parameters. The concentration of Cu21
ions for induction depends on the copper-resistance of the
host strain from 0.01 mM (no CUP1 gene) to 0.5 mM (.6
gene copies).
The expression of heterologous proteins in yeasts other
than S. cerevisiae has become more popular over the past
few years particularly in the methylotrophic yeast Pichia
pastoris and Hansenula polymorpha. Alcohol oxidase
(AOX), the first enzyme in the methanol utilization path-
way in P. pastoris, is dramatically induced in cells grown on
methanol as the sole carbon source [57]. A similar physi-
ologic response has been reported for the H. polymorpha
methanol oxidase (MOX) [58]. By using recombinant plas-
mids containing the AOX or MOX gene promoters or the
promoter for the formate dehydrogenase (FMDH) gene
[64], it has been possible to produce a number of heterolo-
gous gene products to high levels in the methylotrophic
yeasts [for a general review see 35].
Signal sequences
Heterologous protein may be secreted from yeasts using
either a foreign signal (often derived from the protein be-
ing secreted) or a yeast signal. Since signal sequences are
recognized with low specificities in yeast [65], it could be
assumed that foreign signals would work as efficiently as
those from yeast but this is often not the case. Early at-
tempts to secrete foreign proteins from S. cerevisiae utilized
the protein’s own signal [66–68]: the expression levels were
very often very low with only a proportion of the protein
being secreted. Thus the use of foreign leaders often results
in intracellular accumulation. Therefore, for most cases of
heterologous protein secretion from yeast it is preferable to
use a yeast signal sequence. Much work has been carried
out using homologous S. cerevisiae signal sequences. The
most widely used are the signal peptides from acid phos-
phatase [69], invertase [51,70] and a factor [71–73]. Many
foreign proteins have now been secreted from yeast using
the a-factor leader and this system has been demonstrated
to be generally applicable.
Yeast terminators
Yeast transcriptional terminators are usually present in ex-
pression vectors for efficient mRNA 39 end formation. Ter-
minators of prokaryotic  or higher eukaryotic genes are
normally not active in yeasts though there are some excep-
tions such as the Drosophila ADE8 gene [74]. Efficient
termination is required for maximal expression; indeed
Zaret and Sherman [75] demonstrated that deletion of ‘ter-
mination’ sequences 39 of the CYC1 gene resulted in longer
mRNA and a dramatic reduction in mRNA level.
In order to simplify the vector’s construction, the yeast
terminator corresponding to the yeast promoter is usually
used (eg. TRP1, ADH1, PHO5 or GAP); another alterna-
tive is the use of a terminator from 2 l circle, eg. FLP [67]
or D gene terminator [76].
Comparison of prokaryotic and eukaryotic
cell expression
The choice of an expression system for the high-level pro-
duction of recombinants proteins depends on many factors.
These include scientific biological criteria such as cell
growth characteristics, expression levels, intracellular and
extracellular expression, posttranslational modifications
and biological activity of the protein of interest as well as
its  intended  use. In addition, commercial patent-related
criteria also play a role in chosing the appropriate expres-
sion system. The relative advantages of the yeast expres-
Table 3. Promoters for heterologous gene expression
Promoter Culture conditions Expression References
Alcohol dehydrogenase I (ADH I) High (2–5%)glucose constitutive [48]
Alcohol dehydrogenase II (ADH II) Low (0.1–0.2%)glucose inducible [53]
Phosphoglycerate kinase (PGK) High (2–5%)glucose constitutive [49]
Triose phosphate isomerase (TPI) High (2–5%)glucose constitutive [50,51]
Glyceraldehyde-3-phosphate High (2–5%)glucose constitutive [52]
dehydrogenase (GAPDH)
Acid phosphatase (PHO5) Phosphate-deficient medium inducible [54]
Cytochrome c1 (CYC1) Glucose as carbon source repressible [55]
Metallothionein (CUP1) Copper (0.03–0.1 mM) inducible [56]
Alcohol oxidase (AOX) Methanol inducible [57]
Methanol oxidase (MOX) Methanol inducible [58]
Galactose-regulated genes Galactose inducible [59]
(GAL1, GAL7, GAL10)
50
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sion system as compared to bacterial or mammalian cell
expression systems will be briefly described in this para-
graph; for a more exhaustive treatment see the review of
Marino [77].
In comparison with yeasts or mammalian cells, the major
drawbacks of expression in E. coli are the inability to per-
form many of the posttranslational modifications found in
eukaryotic proteins, the lack of a secretion mechanism for
the efficient release of protein into the culture medium, the
limited ability to facilitate extensive disulfide bond forma-
tion and the production of inclusion bodies (for a general
review, see [78]). Many eukaryotic proteins retain their full
biological activity in a nonglycosylated form; therefore,
they can be produced in E. coli; for those which require
glycosylation or for those whose complex tertiary structure
depends in part on disulfide bond formation, yeast and
mammalian cell expression systems are necessary. Indeed,
a particular advantage of these two systems is that the
foreign protein may be directed into the secretory pathway
usually by fusion of the mature form of the recombinant
protein to a given peptide signal. Along the secretory path-
way protein folding, disulfide bond formation and glycosy-
lation take place. Secretion  of  properly folded proteins
which is crucial for full biological activity, is one of the
major factors determining the choice of yeasts or mammal-
ian cells as hosts for heterologous protein expression. This
is due to the fact that the direct capture of active product
from conditioned medium eliminates the need for costly
low-yielding cell-disruption or refolding steps [79].
Glycosylation is both the most common and the most
complex form of posttranslational modification [80]. The
majority of therapeutically relevant proteins are glycosy-
lated in their natural forms and should also be glycosylated
as recombinant proteins in order to get the correct biologi-
cal activity. Thus, monitoring of glycosylation pattern in
quality control of recombinant proteins to assure product
safety, efficiency and consistency has become increasingly
important. Whereas N-glycosylation pathways associated
with the endoplasmic reticulum are highly conserved be-
tween yeast and mammalian cells, chain elongation and
termination occurring in the Golgi apparatus are different
as outlined below. Accordingly, yeast cells recognize the
same N-glycosylation amino acid sequence as higher eu-
karyotic cells. The glycosyl groups on yeast glycoproteins
consist primarily of mannose residues appended in differ-
ent linkages to the core glycosyl units (for review, see [27]).
Since the recombinant glycoproteins generated in S. cere-
visiae are of the high-mannose type, they will be recognized
by mannose receptors on various cells and removed when
injected into the circulation of mammalian species. In addi-
tion, non-human glycosylation patterns are potentially im-
munoreactive. In fact, S. cerevisiae is known to synthesize
large polymannans consisting of 50 to 100 mannose resi-
dues, a phenomenon also referred to as hyperglycosylation.
The bulkiness of these glycans may considerably impair
biological activity of the recombinant protein and, there-
fore, negate any advantage of the microbial eukaryote S.
cerevisiae expression system over E. coli or mammalian
cells. Mannan mutants (mnn) have been isolated, which
synthesize shorter mannan chains but do not grow as well
as other yeast strains. Other yeast species such as P. pastoris
and H. polymorpha seem less prone to hyperglycosylating
heterologous proteins [40]. The  average mannose chain
length produced in the latter two yeasts is only 8–14 mono-
mers which is comparable with complex type glycans. In
fact, in all cases of recombinant proteins with intrinsic com-
mercial value for use as catalysts or as model compounds
to rationally design biomimetics, methylotrophic yeasts are
now the preferred option as expression systems [57].
Because of the hyperglycosylation occurring in some
yeast expression systems, in many cases mammalian cells
are the preferred host cells for the generation of recombi-
nant glycoprotein therapeutics. For these aspects the
reader is referred to [81]. In the special case of recombinant
glycosyltransferases an additional drawback of higher eu-
karyotic cell hosts is the observation that these cells may
express silenced glycosyltransferases genes upon transfec-
tion [82,83]; this may lead to confusion in interpreting the
specificities of recombinant glycosyltransferases. More-
over, animal cells are known to release a number of endo-
genous Golgi-associated glycosyltransferases during
growth [84,85] which may obscure the specificity of the
recombinant enzyme to some extent. Such a problem does
not exist when using E. coli or yeasts as expression systems
because of their limited repertoire of glycosyltransferases
which   is restricted   to mannosyl-, glucosyl- and core
GlcNAc-transferases [86].
In summary, the selection of a particular expression sys-
tem from E. coli, yeasts or mammalian cells depends on the
nature and use of the recombinant protein and the related
production costs. The yeast expression system combines the
ease, simplicity and low costs of bacterial expression sys-
tems: Like bacteria, yeasts are simple to cultivate on inex-
pensive growth media. The reader is referred to Datar et al.
[87] who have analyzed the  economic issues associated
with protein production in bacterial and mammalian cells:
They concluded that for each recombinant protein, it is
necessary to evaluate the production process as a whole.
Since each protein has its own requirements in terms of
folding, glycosylation and maturation-associated cleavage
or other posttranslational modifications, extensive pilot-
scale studies are essential for rigorous comparative evalu-
ations.
Specific section
Sialyltransferases
Sialyltransferases are glycosyltransferases that transfer
sialic acid  from the donor substrate CMP-sialic acid  to
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different types of oligosaccharides according to the follow-
ing general reaction:
CMP-N-ACETYLNEURAMINATE 1 b-D-GALAC-
TOSYL-1,4-N-ACETYL-b -D-GLUCOSAMINE-R
fi
CMP 1 a-N-ACETYLNEURAMINYL-2,6/3-b -
D-GALACTOSYL-1,4-N-ACETYL-b -
D-GLUCOSAMINE-R
As shown in Table 1 the sialyltransferases are grouped
according to the linkage  type they catalyze. Within the
family of sialyltransferases and in contrast to other families
of glycosyltransferases, practically no sequence homology
was observed except for two conserved motifs, the “L-sia-
lylmotif” and the “S-sialylmotif” located in the catalytic
domain. Both  of them have been shown  by Datta  and
Paulson [88,89] to be involved in the binding of the donor
substrate.
The yeast expression data are compiled on Table 4.
a-2,3-Sialyltransferases
To date four different a-2,3-sialyltransferases have been
cloned. Their in vivo substrate specificities have been ex-
tensively studied by Tsuji et al. [16]. Only one out of these
four has yet been expressed in yeasts, the ST3GalIII (Gen-
Bank Accession # m97754). It has the following specificities
for the acceptor substrates, in the order of decreasing rate
of   the reaction: Galb1,3GlcNAc. Galb1,4GlcNAc .
Galb1,3GalNAc.
A truncated form (aa 29-374) of the rat ST3GalIII [94]
has been expressed in S. cerevisiae H23 and H626 [90]. The
enzyme was N-terminally fused to the hsp150D polypep-
tide, a carrier which has previously been used for heterolo-
gous proteins to confer proper folding and secretion into
the growth media [95]. The enzyme was shown to be active
but remained intracellularly. Mattila et al. [90] showed that
the protein was poly-mannosylated on one or both of its
potential N-glycosylation sites indicating that the enzyme
was transported at least to the Golgi apparatus. Interest-
ingly, tunicamycin treatment abolished activity completely
suggesting that glycosylation of ST3GalIII is required for
proper folding and activity. Since the enzyme remained
intercalated in the cell wall whole live yeast cells were used
as enzymatic catalyst for the synthesis of sialyl a2,3-N-ace-
tyllactosamine a prerequisite for the sialyl LewisX epitope
synthesis. Thus 110 mU/l were obtained while the same
enzyme expressed in insect cells has been shown to yield 25
U/l after 72 h of incubation [96].
a-2,6-Sialyltransferases
The family of a-2,6-sialyltransferases can further be subdi-
vided by the acceptor used. One subgroup acts on galactose
while the other incorporates sialic acid on N-acetylgalac-
tosamine. To date, only one has been expressed in yeast.
Krezdorn et al. [91] expressed a full-length form of human
a-2,6-ST6Gal (GenBank Accession # 317247 EC 24991)
which incorporates sialic acid on Galb1, 4GlcNAc. The first
host to be used was a protease-deficient strain of S. cere-
visiae BT150 which later was cultivated and up-scaled by
Borsig et al. [92] to the 150 1 scale. It yielded an activity of
0.3 U/1 in the yeast lyophilisate. The ST6Gal was produced
in a glycosylated form containing two oligomannose units
as shown by Endoglycosidase-H treatment. As concluded
by pulse chase analysis, it was located in the endoplasmic
reticulum (ER) or an early Golgi compartment. It ap-
peared to be translocated into the endoplasmic reticulum
by a posttranslational mechanism as not uncommonly
found in this host (for a review, see [97]). The recombinant
ST6Gal had similar Michaelis constants (101 lM) as the
native rat enzyme (158 lM) for the donor substrate. The
constants for the acceptor substrates however were mark-
edly different. For the recombinant form a Km of 4.65 mM
was determined while the native rat enzyme revealed a Km
of 1.67 mM. Subsequently, this recombinant ST has been
used by van Dorst [98] to explore the substrate specificities
of ST6Gal.
Table 4. Expression of sialyltransferases in yeast
Enzyme Form Vector Host cell Specific activity Volume localization reference
(mU/mg specific
Protein) activity
(mU/I)
a2,3 ST soluble hsp 150D pKTH4636 S. cerevisiae H23, not reported 110 cell wall [90]
fusion-protein S. cerevisiae H626
a2,6 ST full-length pDP34 S. cerevisiae BT150 0.3 300 ER, early Golgi [91,92]
soluble pDP34 S. cerevisiae BT150 1 cell Borsig et al.,
unpublished
a2,6 ST soluble pPIC9 P. pastoris KM71 0.086 300 media [93]
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To facilitate downstream processing, attempts were
made at expressing ST6Gal as a soluble form to release it
into the supernatant. A truncated form lacking the trans-
membrane domain has thus been expressed in S. cerevisiae
BT150: The enzyme was weakly active (1 mU/l). The reason
for this low activity was not further explored but might
have been due to hyperglycosylation of the N-glycosylation
site located close to the catalytic portion [92]. The same
enzyme was therefore expressed in P. pastoris yielding a
volumetric activity 0.3 U/l (manuscript in preparation).
Galactosyltransferases
b-1,4-Galactosyltransferase
b-1, 4-galactosyltransferase (gal-T1) (EC 2.4.1.38 GenBank
Accession M22921) is one of the best known glycosyltrans-
ferases. Its general reaction is
UDP-GALACTOSE 1 N-ACETYL-b-
D-GLUCOSAMINYLGLYCOPEPTIDE
fi
UDP 1 b-D-GALACTOSYL-1,4-N-ACETYL-b -
D-GLUCOSAMINYLGLYCOPEPTIDE
The enzyme also catalyzes the transfer of galactose to glu-
cose in the presence of a-lactalbumin (E.C. 2.4.1.22) and
many other glycoconjugates exhibiting terminal b-
GlcNAc-residues. Gal-T1 (see Table 1) is a Golgi-associ-
ated glycosyltransferase located in trans Golgi cisternae
and possibly on cell surfaces. The enzyme is a type II mem-
brane protein consisting of a single polypeptide. Gal-T1 is
solubilized in vivo and released from the cells in an enzy-
matically truncated active form [85]. The peptide contains
a single N-glycosylation site and various O-glycosylation
sites [99].
Krezdorn et al. [100] were the first to report heterolo-
gous expression of full length gal-T1 using a yeast expres-
sion system (Table 5). The vector used contained the PHO5
promoter, the cDNA encoding full-length gal-T1 and the
PHO5 terminator. The PHO5 promoter fragment lacks the
upstream regulatory fragments and therefore acts like a
constitutive promoter. Recombinant gal-T1 produced in
the S. cerevisiae BT150 strain was investigated by metabolic
labeling followed by immunoprecipitation and shown to be
retained in the endoplasmic reticulum [91]. Krezdorn et al.
[100] assumed that the signal for Golgi targeting retention
was not recognized in yeasts and this was further supported
by the results obtained with an other glycosyltransferase,
the ST6Gal [91]. The transmembrane anchor which acts as
the secretion leader for these type II membrane proteins,
appears to determine the expression level of gal-T1 which
was found to be much lower than the expression level of
gal-T1 fused to the membrane anchor of the a1,2mannosyl-
transferase (Mnt1p) despite the fact that all the transfor-
mants produce equal mRNA level; this may be due to the
fact that the transmembrane domain of gal-T1 contains
amino acids which are rarely used in yeast genes [101]. In
addition, the membrane anchor of the Mnt1p was able to
target gal-T1 to the yeast Golgi complex [102]. Altogether,
this could also explain the high difference observed be-
tween the expression level obtained by Krezdorn et al.
[100] (gal-T1 represents 0.01% of crude extract protein)
and Schwientek and Ernst [101] (gal-T1 represents 0.15%
of crude extract protein).
Since the handling of a membrane protein for purifica-
tion and use in vitro for organic synthesis is difficult, at-
tempts were made to express soluble forms of gal-T1
[101,104]. In both cases, the transmembrane domain was
replaced by a yeast signal sequence which allows transloca-
tion to the secretory pathway. When the invertase signal
sequence was used, gal-T1 was produced as a soluble en-
zyme retained in the yeast cell [104]; when the a-factor
signal sequence was used, 62% of the produced soluble
gal-T1 was secreted into the culture medium [101]. This
major difference in the protein localization was probably
due to the signal peptide.
On the laboratory scale Kleene et al. [104] obtained an
expression level of 200 mU/l culture. By using fermentation
in fed batch technique it was possible to increase the ex-
pression level of recombinant soluble gal-T1 from 200
mU/l to 705 mU/l [105]; this study also demonstrated for
the first time that heterologous expression of a glycosyl-
transferase is possible on a large scale (use 150 l fermen-
tor). This offers a good alternative to natural sources of
gal-T1 like human milk or bovine colostrum.
The recombinant soluble gal-T1  expressed in S. cere-
visiae BT150 was purified to homogeneity through three
successive affinity chromatographies and was shown to be
N-hyperglycosylated [103]. The N-hyperglycosylation had
no impact on gal-T1 activity since it was observed that the
specific activity of the purified recombinant gal-T1 was on
the same order as the catalytic activity of the human gal-T1.
The N-hyperglycosylated biochemically pure recombinant
gal-T1 was shown to be very heterogeneous when analyzed
by immunoblotting. In order to obtain a more homogene-
ous protein, the unique N-glycosylation site was removed
by using site directed-mutagenesis; the soluble mu-
tagenized  recombinant gal-T1 expressed in S. cerevisiae
BT150 was scaled up to 60 U in a 150 l fermentor which
represents an expression level of 400 mU/l. After purifica-
tion the specific activity of the soluble mutated recombi-
nant gal-T1 was 6.9 U/mg and the Km values were
comparable to those reported for the human gal-T1.
Aiming at simplifying purification of recombinant gal-T1
expressed in S. cerevisiae, Borsig et al. [106] introduced an
His6-tag to the N-terminus of gal-T1 (his-gal-T1). Binding
efficiency of his-gal-T1 was found to be impaired by the
bulky N-glycan previously described by Malissard et al.
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Table 5. Expression of gal-T1 in yeasts
Enzyme Form Vector Host cell Specific activity Volume specific Localization Reference
(mU/mg protein) activity (mU/l)
gal-T1 Full length pDP34 S. cerevisiae BT150 0.42 — intracellular [100]
pGTraI S. cerevisiae BJ1991 level of detection intracellular [101]
Soluble pDP34 S. cerevisiae BT150 0.66 705 (fermentation) intracellular [105]
pMFGTI S. cerevisiae BJ1991 — — secreted [101]
pPIC9 P. pastoris KM71 15 400 (lab scale) secreted Malissard et al.,
unpublished
Soluble fused to phMGTI S. cerevisiae BJ1991 1.47 — intracellular [101]
N-terminus part of Mnt1
soluble N-deglycosylated pDP34 S. cerevisiae BT150 220 (lab scale) intracellular [103]
425 (fermentation) intracellular [103]
(fermentation) intracellular [136]
pPIC9 P. pastoris KM71 0.17 350 (lab scale) intracellular [Malissard et al.,
unpublished]
His-tagged soluble pDP34His S. cerevisiae BT150 — 25 (lab scale) intracellular [106]
His-tagged soluble pDP34His S. cerevisiae BT150 — 15.6 (lab scale) intracellular [106]
N-deglycosylated
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[103] close to the His-tag. Removal of the unique N-glyco-
sylation site restored binding of his-gal-T1 to the Ni-NTA
resin.
Recently, gal-T1 was also expressed in P. pastoris. Briefly,
gal-T1 was found to be secreted and active (400 mU/l on
the laboratory level) while the non-N-glycosylated form
was active but not secreted (Malissard et al. manuscript in
preparation). These data suggest that N-glycosylation of
gal-T1 is required for efficient secretion by P. pastoris al-
though it is not required for enzyme activity. Such results
were already reported for proteins expressed in S. cere-
visiae; indeed the secretion of acid phosphatase [107], Mu-
cor  pulsus rennin [108] and an analog of human tissue
plasminogen activator [109] are inhibited when N-glycosy-
lation sites are removed. For expression in P. pastoris there
is no general rule concerning the need of N-glycosylation
for efficient secretion. Indeed, secretion efficiency of a-N-
acetylgalactosaminidase is strongly decreased when the N-
glycosylation is missing [110], but Tsujikawa et al. [111]
reported secretion of a variant of human single-chain urok-
inase-type plasminogen activator without an N-glycosyla-
tion site. The gal-T1 produced by P. pastoris is recognized
directly by polyclonal antibodies and when analyzed on
SDS-PAGE it comigrates with the human gal-T1 indicating
that  no  hyperglycosylation  takes place (Malissard et al.
unpublished results). The secretion of gal-T1 in the culture
medium represents a major advance with respect to pro-
duction of enriched preparations.
In recent years, interest for gal-T1 and for glycosyltrans-
ferases in general has been aroused by their potential use-
fulness as tools for the synthesis of oligosaccharides in vitro
(for reviews, [112–114]), for the remodeling of glycan
chains of natural or recombinant proteins and in case of
gal-T1 for the enzymic galactosylation of non-natural gly-
cosides.
Early uses of natural gal-T1 in synthesis have been re-
ported by Barker et al. [115] who incorporated Gal into
GlcNAc immobilized on Sepharose. More recently,
Herrmann et al. [116] reported the  use of  transformed
whole yeast cells carrying a plasmid for the heterologous
expression of a soluble human gal-T1 for the synthesis of
N-acetyllactosamine.
Above we gave two examples where gal-T1 was used for
the synthesis of disaccharides, but it can also be used in
combination with organic synthesis or with other glycosyl-
transferases for the synthesis of more complex oligosaccha-
rides [117]. In 1997, Unverzagt [118] described an effective
use of gal-T1 and ST6Gal to complete a chemical synthesis
which was difficult to achieve by chemical means. A hep-
tasaccharide asparagine conjugate was galactosylated and
sialylated in the presence of alkaline phosphatase to afford
a sialylated undecasaccharide in 86% yield. There are many
other examples where gal-T1 in combination with other
glycosyltransferases has been used for the synthesis of large
glycan structures [119–122].
Gal-T1 can also be used for remodeling of glycan chains
of natural or recombinant glycoproteins. Witte and cowork-
ers [123] reported the synthesis of an unnatural glycoform
of ribonuclease. Ribonuclease B contains a single N-linked
glycosylation site and exists as a series of high-mannose
glycoforms. Treatment with endoglycosidase H gives the
ribonuclease derivative, GlcNAc-RNase, with a single
GlcNAc attached at this site. Treatment with gal-T1 and a
cofactor recycling system gives rise to the disaccharide-
linked protein in 76% yield. Further treatment with a-1,3-
fucosyltransferase (Fuc-T) or a-2,3-sialyltransferase (ST)
or ST followed by Fuc-T gives rise to the predicted glyco-
protein products in yields of 72%, 85% and 74% (for the
Fuc-T-catalyzed step), respectively. The product of the
three-step synthesis is a protein-bound form of sialyl Lewis
x. Other examples can be found in Ju and Kean [124] and
Schneider et al. [125].
Fucosyltransferases
Among the fucosyltransferases indicated in table 1 only
Fuc-TIII and Fuc-TV have been described as recombinant
enzymes expressed in lower eukaryotes.
Fucosyltransferase III
Fuc-TIII (Galactoside 3(4)-L-fucosyltransferase E.C.
2.4.1.65 (Genbank accession X87810) also known as blood
group Lewis alpha-4-fucosyltransferase catalyzes the fol-
lowing reaction:
GDP-L-FUCOSE 1 1,3-b-D-GALACTOSYL-N-
ACETYL-D-GLUCOSAMINYL-R
fi
GDP 1 1,3-b-D-GALACTOSYL-(a-1,4-L-FUCOSYL)-
N-ACETYL-D-GLUCOSAMINYL-R
This enzyme has been expressed in P. pastoris [34] as a
truncated form to facilitate release to the supernatant. In
fact, it was observed that the enzyme remained cell-associ-
ated for 30 h of continuous fermentation before being re-
leased. The   enzyme present   in the   supernatant   was
detected as a 43 kDa band by SDS-gel electrophoresis and
immunoblotting and shown to account for 10% of the pro-
teins in the supernatant. The yield was 113 U per liter. The
enzymic properties were characterized using a variety of
small molecular weight acceptors. As predicted, the enzyme
incorporated fucose into type 11 structures and at a much
lower rate into type 2 structures. In fact, LacNAc was not
an acceptor at all. As already shown by Herrmann et al. for
1the linkage types are defined in Table 1.
55
The yeast expression system 135
b1, 4gal-T1 [116], the cell-associated enzyme could be used
as an immobilized (reusable) catalyst to synthesize a se-
lectin ligand [39].
Fucosyltransferase V
Fuc-TV has been expressed in the filamentous fungus As-
pergillus niger var. Awamori. This type  of  fucosyltrans-
ferase belongs to a gene family which has been described
in humans [126]. The physiological significance and expres-
sion of this enzyme have not been elucidated except for a
report describing its expression in pancreatic cancer [127].
Its general reaction is as follows:
GDP-L-FUCOSE 1 1,4-b-D-GALACTOSYL-
N-ACETYL-D-GLUCOSAMINYL-R
fi
GDP 1 1,3-b -D-GALACTOSYL-(a-1,3-L-FUCOSYL)-
N-ACETYL-D-GLUCOSAMINYL-R
The acceptor may contain a terminal a2,3 sialic acid; in this
case the kcat is 6.5 times lower. The enzyme has been ex-
pressed as a fusion protein linked to glucoamylase by a kex
2 proteolytic site. The enzyme was then truncated to a
soluble catalytically active form whose cumulative activity
reached 300 U/l in the supernatant. Downstream process-
ing involved a 20–60% ammonium sulfate cut and chroma-
tography on phenyl-Sepharose [128]. Besides extensive
kinetic characterization an inhibitor was developed [129]
showing the usefulness of recombinant enzymes in almost
unlimited supply.
a-1,2-Mannosyltransferase
The best characterized mannosyltransferases are those in S.
cerevisiae which harbour a family of related genes known
as KRE2/MNT1. The general reaction is as follows:
GDP-D-MANNOSE 1 MANNOSE a1-R
fi
GDP 1 MANNOSE a1,2 MANNOSE a1-R
For standard assays a-methyl-mannose has been used.
Since in yeasts the a1,2 linked mannose residues occur in
the core N-glycan, in the outer chains, as well as in O-linked
glycans, delineation of the specificity of a gene product with
mannosyltransferase activity is necessary to assign the
physiological function. For this purpose two mannosyl-
transferase gene  products from S. cerevisiae, i.e.. Ktr1p,
Kre2p/Mntlp, have been expressed in P. pastoris and their
enzymic properties compared.
Both enzymes were expressed as truncated enzymes
without cytoplasmic and transmembrane  domains fused
with the cleavable signal sequence of the PHO1 gene prod-
uct. The released enzymes were identified by SDS-PAGE
and immunoblotting and shown to be very pure. The sol-
uble form  of  recombinant  Ktrlp  amounted to  400 mg/l
while Kre2p was 40 mg/l. Substrate specificity studies then
showed that both enzymes can utilize N-type glycans [130].
Cell engineering
Heterologous expression of human glycoproteins in yeasts
has been on the agenda of several companies since the
early eighties. Soon it became obvious that the glycosyla-
tion pattern of yeast consisting of the polymannose outer
chains differs from the complex N-glycans present in hu-
man glycoproteins (for review, see [131]). Moreover, the
O-glycosidic glycan chains are entirely different. Impor-
tantly, the mechanism of core N-glycosylation in human
cells is highly conserved in many respects and indistin-
guishable from the mechanisms in yeast. The divergence of
the N-glycosylation pathway between higher and lower eu-
karyotes occurs in the Golgi apparatus where a mannosi-
dase I trims the oligomannose structure to Man5GlcNAc2.
N-acetylglucosaminyltransferase I (EC 2.4.1.101) thereaf-
ter elongates this core oligomannose structure according to
the following reaction:
UDP-N-ACETYL-D-GLUCOSAMINE 1 a-
D-MANNOSYL-1,3-(R1)-b -D-MANNOSYL-R2
fi
UDP 1 N-ACETYL-b -D-GLUCOSAMINYL-1,2-
ALPHA-D-MANNOSYL-1,3-(R1)-b-D-MANNOSYL-R2
This enzyme is absent in yeast as well as enzymes further
along the pathway involved in structuring a “human type”
biantennary complex N-glycan.
An ambitious endeavour which has been initiated in sev-
eral laboratories aims at introducing the complete metabo-
lic armamentarium into yeast to enable them to structure
complex N-glycans. The strategy takes advantage of several
glycosylation mutants such as Dochl, Dmnnl and Dmnn4
[132] to prevent polymannosylation. However, in order to
synthesize the substrate for N-acetylglucosaminyltrans-
ferase I an a-mannosidase I-like enzyme must cleave the
a1,2 linked mannose residues. This has recently been ren-
dered possible by expressing the a1,2mannosidase from
Aspergillus saitoi in yeast cells. Elegantly, to have this en-
zyme working at the proper site of the secretory pathway,
a Golgi to ER retrieval signal (the HDEL sequence) was
linked to the C-terminus [132]. The consequence of the
introduction of this enzyme to N-glycosylation was exam-
ined on carboxypeptidase Y and on cell wall mannoprote-
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ins. Trimming to the Man5 species was found to be approx
25% and 10%, respectively. To achieve elongation and ter-
mination of complex glycans, additional glycosyltrans-
ferases and nucleotide sugar transporters are required.
Surprisingly, heterologous expression of human b1,4galac-
tosyltransferase led to the incorporation of galactose into
several yeast proteins [103], suggesting the presence of the
metabolic pathways to synthesize UDP-gal and to trans-
port it across the Golgi membranes. This has in fact been
confirmed recently by a direct demonstration of a UDP-
gal/UMP antiporter in S. cerevisiae Golgi membranes [133].
The accomplishment of the goal to develop a S. cerevisiae
strain that produces “humanized” heterologous glycopro-
teins appears still remote. However, the endeavour may
spin off more interesting and unexpected results.
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